Kiniksa Pharmaceuticals International (KNSA) Net Margin (2021 - 2026)

Kiniksa Pharmaceuticals International's Net Margin history runs 6 years deep, the most recent figure standing at 10.54% for Q1 2026.

• Quarterly Net Margin rose 435.0% year-over-year to 10.54% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11.83% (up 943.0% YoY) and the FY2025 annual result came in at 11.09%, up 1457.0% from the prior year.
• Net Margin was 10.54% for Q1 2026 at Kiniksa Pharmaceuticals International, down from 15.01% in the prior quarter.
• Across five years, Net Margin topped out at 226.05% in Q3 2022 and bottomed at 99.56% in Q4 2023.
• A 5-year average of 9.85% and a median of 6.2% in 2025 frame the typical range for Net Margin.
• Annual changes were most pronounced in 2022 — Net Margin surged 47858 bps — and 2023, when it tumbled 28576 bps.
• Kiniksa Pharmaceuticals International's Net Margin stood at 186.2% in 2022, then sank by 153 bps to 99.56% in 2023, then soared by 116 bps to 15.99% in 2024, then fell by 6 bps to 15.01% in 2025, then declined by 30 bps to 10.54% in 2026.
• Business Quant data shows KNSA's Net Margin at 10.54% in Q1 2026, 15.01% in Q4 2025, and 10.19% in Q3 2025.